Low Annexin A1 level in HTLV-1 Infected Patients might be a Potential Biomarker for the Clinical Progression and Diagnosis of HAM/TSP
Background: Human T-lymphotropic virus 1 (HTLV-1) is etiologically associated with the chronic inflammatory neurodegenerative disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) Annexin A1 (AnxA1) is an anti-inflammatory protein with proposed neuroprotective and anti-neuroinflammatory functions. We hypothesized that ANXA1 gene expression may be dysregulated in HTLV-1-infected HAM/TSP patients.
Methods: This study involved 37 individuals infected with HTLV-1, including 21 asymptomatic (AS) carriers and 16 with HAM/TSP, and a control group of 30 individuals negative for HTLV-1 and HTLV-2. For AS HTLV-1-positive and HAM/TSP patients, ANXA1 and formyl peptide receptor (FPR1, FPR2 and FPR3) expression and HTLV-1 proviral load (PVL) in peripheral blood cells were evaluated by real-time quantitative PCR (qPCR), and plasma AnxA1 levels were determined by enzyme-linked immunosorbent assay (ELISA).
Results: ANXA1 gene expression was increased in the AS group compared with the HAM/TSP and control groups, but the differences were not statistically significant. FPR1 gene expression was higher in patients with HTLV-1 than in controls (AS, p= 0.0032; HAM/TSP, p< 0.0001). Plasma AnxA1 levels were higher in the AS group than in the HAM/TSP group (p= 0.0045), and PVL was higher in patients with HAM/TSP than in AS individuals (p= 0.0162). The use of a combined ROC curve using Annexin 1 levels and proviral load significantly increased the sensitivity and specificity to predict progression to HAM/TSP (AUC = 0.851 and AUC = 0.937, respectively, to AUC=1,000).
Conclusions: Our results suggest that AnxA1 may be dysregulated in HAM/TSP patients. Serological detection of AnxA1 in association with proviral load may provide a prognostic biomarker for HTLV-1-associated neurodegenerative disease.
Figure 1
Figure 2
Figure 3
Figure 4
Due to technical limitations, full-text HTML conversion of this manuscript could not be completed. However, the latest manuscript can be downloaded and accessed as a PDF.
This is a list of supplementary files associated with this preprint. Click to download.
Posted 29 Dec, 2020
On 21 Jan, 2021
Received 20 Jan, 2021
Received 20 Jan, 2021
On 31 Dec, 2020
On 31 Dec, 2020
On 31 Dec, 2020
Received 30 Dec, 2020
Received 30 Dec, 2020
Received 30 Dec, 2020
Received 30 Dec, 2020
Received 30 Dec, 2020
Received 30 Dec, 2020
Received 30 Dec, 2020
Received 30 Dec, 2020
Received 30 Dec, 2020
Received 30 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
Invitations sent on 25 Dec, 2020
On 25 Dec, 2020
On 24 Dec, 2020
On 24 Dec, 2020
On 18 Dec, 2020
Low Annexin A1 level in HTLV-1 Infected Patients might be a Potential Biomarker for the Clinical Progression and Diagnosis of HAM/TSP
Posted 29 Dec, 2020
On 21 Jan, 2021
Received 20 Jan, 2021
Received 20 Jan, 2021
On 31 Dec, 2020
On 31 Dec, 2020
On 31 Dec, 2020
Received 30 Dec, 2020
Received 30 Dec, 2020
Received 30 Dec, 2020
Received 30 Dec, 2020
Received 30 Dec, 2020
Received 30 Dec, 2020
Received 30 Dec, 2020
Received 30 Dec, 2020
Received 30 Dec, 2020
Received 30 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
On 25 Dec, 2020
Invitations sent on 25 Dec, 2020
On 25 Dec, 2020
On 24 Dec, 2020
On 24 Dec, 2020
On 18 Dec, 2020
Background: Human T-lymphotropic virus 1 (HTLV-1) is etiologically associated with the chronic inflammatory neurodegenerative disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) Annexin A1 (AnxA1) is an anti-inflammatory protein with proposed neuroprotective and anti-neuroinflammatory functions. We hypothesized that ANXA1 gene expression may be dysregulated in HTLV-1-infected HAM/TSP patients.
Methods: This study involved 37 individuals infected with HTLV-1, including 21 asymptomatic (AS) carriers and 16 with HAM/TSP, and a control group of 30 individuals negative for HTLV-1 and HTLV-2. For AS HTLV-1-positive and HAM/TSP patients, ANXA1 and formyl peptide receptor (FPR1, FPR2 and FPR3) expression and HTLV-1 proviral load (PVL) in peripheral blood cells were evaluated by real-time quantitative PCR (qPCR), and plasma AnxA1 levels were determined by enzyme-linked immunosorbent assay (ELISA).
Results: ANXA1 gene expression was increased in the AS group compared with the HAM/TSP and control groups, but the differences were not statistically significant. FPR1 gene expression was higher in patients with HTLV-1 than in controls (AS, p= 0.0032; HAM/TSP, p< 0.0001). Plasma AnxA1 levels were higher in the AS group than in the HAM/TSP group (p= 0.0045), and PVL was higher in patients with HAM/TSP than in AS individuals (p= 0.0162). The use of a combined ROC curve using Annexin 1 levels and proviral load significantly increased the sensitivity and specificity to predict progression to HAM/TSP (AUC = 0.851 and AUC = 0.937, respectively, to AUC=1,000).
Conclusions: Our results suggest that AnxA1 may be dysregulated in HAM/TSP patients. Serological detection of AnxA1 in association with proviral load may provide a prognostic biomarker for HTLV-1-associated neurodegenerative disease.
Figure 1
Figure 2
Figure 3
Figure 4
Due to technical limitations, full-text HTML conversion of this manuscript could not be completed. However, the latest manuscript can be downloaded and accessed as a PDF.